Uncategorized

Intercept’s next-gen FXR agonist fails Phase 2 in latest setback for Italian-owned pharma

Published

3 hours ago

on

May 5, 2026

By

Temp User

Intercept Pharmaceuticals’ attempt at creating a next-generation FXR agonist for certain forms of liver inflammation appears to have ended.

The drug developer’s INT-787 showed “no clear evidence of potential” in patients with severe alcohol-associated hepatitis …

Related Topics:

Leave a Reply

Uncategorized9 years ago

These ’90s fashion trends are making a comeback in 2017
Contributors9 years ago

The final 6 ‘Game of Thrones’ episodes might feel like a full season
Uncategorized9 years ago

According to Dior Couture, this taboo fashion accessory is back
Uncategorized9 years ago

Uber and Lyft are finally available in all of New York State
Uncategorized9 years ago

Phillies’ Aaron Altherr makes mind-boggling barehanded play
Uncategorized9 years ago

The old and New Edition cast comes together to perform

Exit mobile version